Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis

<div>Cumulative incidence of HCC in patients with hepatitis B-caused cirrhosis before (a) and after matching with those with and without FZHY use. (b) Cumulative incidence of HCC in patients before (c) and after matching (d) for different times of FZHY use. HCC: hepatocellular carcinoma; FZHY: Fuzheng Huayu capsule.</div>

Evidence-Based Complementary and Alternative Medicine

fig2

Figure 2

Figure 2: Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis 